Search

Your search keyword '"Rothe, Michael"' showing total 837 results
Start Over Author "Rothe, Michael"
837 results on '"Rothe, Michael"'

1. Edge AI Solutions for Spacecraft Failure Management

Author

Ales, Filippo, Krstova, Alisa, Chabot, Thomas, Ghiglione, Max, de Lera, Mario Castro, Hegwein, Florian, Koch, Andreas, Garcia, Carlos Hervas, Harikrishnan, Prem, Mallah, Maen, Ali, Rashid, Rothe, Michael, Hili, Laurent, De Rosa, Sergio, Series Editor, Zheng, Yao, Series Editor, Popova, Elena, Series Editor, Lee, Young H., editor, Schmidt, Alexander, editor, and Trollope, Ed, editor

Published
2025
Full Text
View/download PDF

2. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Worden, Francis P., Pisick, Evan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Khalil, Maged F., Carrizosa, Daniel R., Bauman, Jessica R., Leidner, Rom S., Duvivier, Herbert L., Fu, Siqing, Park, Min S., Yost, Kathleen J., Calfa, Carmen J., Marr, Alissa S., Balmanoukian, Ani S., Behl, Deepti, Cannon, Timothy L., Nabell, Lisle, Powell, Steven Francis, Thota, Ramya, Hinshaw, Dominique C., Gregory, Abigail, Grantham, Gina N., Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

3. Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations

Author

Yoon, John K., Schindler, Jeffrey W., Loperfido, Mariana, Baricordi, Cristina, DeAndrade, Mark P., Jacobs, Mary E., Treleaven, Christopher, Plasschaert, Robert N., Yan, Aimin, Barese, Cecilia N., Dogan, Yildirim, Chen, Vicky Ping, Fiorini, Claudia, Hull, Fritz, Barbarossa, Luigi, Unnisa, Zeenath, Ivanov, Daniel, Kutner, Robert H., Guda, Swaroopa, Oborski, Christine, Maiwald, Tim, Michaud, Véronique, Rothe, Michael, Schambach, Axel, Pfeifer, Richard, Mason, Chris, Biasco, Luca, and van Til, Niek P.

Published
2024
Full Text
View/download PDF

4. Palmitoylcarnitine impairs immunity in decompensated cirrhosis

Author

Zhang, Ingrid Wei, Sánchez-Rodríguez, María Belén, López-Vicario, Cristina, Casulleras, Mireia, Duran-Güell, Marta, Flores-Costa, Roger, Aguilar, Ferran, Rothe, Michael, Segalés, Paula, García-Ruiz, Carmen, Fernández-Checa, José C., Trebicka, Jonel, Arroyo, Vicente, and Clària, Joan

Published
2024
Full Text
View/download PDF

6. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Schuetze, Scott, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Calfa, Carmen J., Farrington, Laura Catherine, Livingston, Michael B., Wentzel, Kristopher, Behl, Deepti, Kier, Yelena, Marr, Alissa S., von Mehren, Margaret, Press, Joshua Z., Thota, Ramya, Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

7. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Brouse, Gregory, Chan, John, Mehmi, Inderjit, Khalil, Maya, Duvivier, Herbert L., Gaba, Anu, Leuva, Harshraj, Thota, Ramya, Yost, Kathleen J., Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

8. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials

Author

Río, Paula, Zubicaray, Josune, Navarro, Susana, Gálvez, Eva, Sánchez-Domínguez, Rebeca, Nicoletti, Eileen, Sebastián, Elena, Rothe, Michael, Pujol, Roser, Bogliolo, Massimo, John-Neek, Philipp, Bastone, Antonella L, Schambach, Axel, Wang, Wei, Schmidt, Manfred, Larcher, Lise, Segovia, José C, Yáñez, Rosa M, Pérez-Maroto, Florencio, de la Cruz, Ana, Casado, José A, Giménez, Yari, Álvarez, Lara, Alberquilla, Omaira, Díez, Begoña, Fernández-García, María, García-García, Laura, Gómez, Ana, Galán, Almudena, Ramírez, Manuel, Salgado, Rocío, Galy, Anne, Lefrere, Francois, Cavazzana, Marina, Leblanc, Thierry, Garcia de Andoin, Nagore, López-Almaraz, Ricardo, Catalá, Albert, Barquinero, Jordi, Rodríguez-Perales, Sandra, Rao, Gayatri, Surrallés, Jordi, Soulier, Jean, Díaz-de-Heredia, Cristina, Schwartz, Jonathan D, Sevilla, Julián, Bueren, Juan A, Bastone, Antonella Lucía, and García de Andoin, Nagore

Published
2024
Full Text
View/download PDF

13. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Sahai, Vaibhav, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Suhag, Vijay, Dib, Elie G., Mehmi, Inderjit, Kadakia, Kunal C., Pisick, Evan, Duvivier, Herbert L., Le, Phat, Li, Rui, Michelin, David P., Wilcox, Ryan E., Grantham, Gina N., Hinshaw, Dominique C., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

14. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Calfa, Carmen J., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Burness, Monika L., Gogineni, Keerthi, Rohatgi, Nitin, Al Baghdadi, Tareq, Conlin, Alison, Gaba, Anu, Hamid, Omid, Krishnamurthy, Jairam, Gavini, Naga Jyothi, Gold, Philip J., Rodon, Jordi, Rueter, Jens, Thota, Ramya, Grantham, Gina N., Hinshaw, Dominique C., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

15. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Ahn, Eugene R., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Calfa, Carmen J., Alva, Ajjai S., Suhag, Vijay, Alese, Olatunji B., Dotan, Efrat, Hamid, Omid, Yang, Eddy S., Marr, Alissa S., Palmer, Martin C., Thompson, Forrest L., Yost, Kathleen J., Gregory, Abigail, Grantham, Gina N., Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

17. Harmonized procedures lead to comparable quantification of total oxylipins across laboratories

Author

Mainka, Malwina, Dalle, Céline, Pétéra, Mélanie, Dalloux-Chioccioli, Jessica, Kampschulte, Nadja, Ostermann, Annika I, Rothe, Michael, Bertrand-Michel, Justine, Newman, John W, Gladine, Cécile, and Schebb, Nils Helge

Subjects
Medical Biochemistry and Metabolomics, Biomedical and Clinical Sciences, Clinical Research, Calibration, Chromatography, Liquid, Humans, Oxylipins, Quality Control, Tandem Mass Spectrometry, eicosanoids, lipidomics, liquid chromatography, mass spectrometry, quantitation, harmonization, plasma lipids, interlaboratory comparison, oxidized fatty acids, lipid mediators, Biochemistry and Cell Biology, Biochemistry & Molecular Biology, Biochemistry and cell biology, Medical biochemistry and metabolomics
Abstract

Oxylipins are potent lipid mediators involved in a variety of physiological processes. Their profiling has the potential to provide a wealth of information regarding human health and disease and is a promising technology for translation into clinical applications. However, results generated by independent groups are rarely comparable, which increases the need for the implementation of internationally agreed upon protocols. We performed an interlaboratory comparison for the MS-based quantitative analysis of total oxylipins. Five independent laboratories assessed the technical variability and comparability of 133 oxylipins using a harmonized and standardized protocol, common biological materials (i.e., seven quality control plasmas), standard calibration series, and analytical methods. The quantitative analysis was based on a standard calibration series with isotopically labeled internal standards. Using the standardized protocol, the technical variance was within ±15% for 73% of oxylipins; however, most epoxy fatty acids were identified as critical analytes due to high variabilities in concentrations. The comparability of concentrations determined by the laboratories was examined using consensus value estimates and unsupervised/supervised multivariate analysis (i.e., principal component analysis and partial least squares discriminant analysis). Interlaboratory variability was limited and did not interfere with our ability to distinguish the different plasmas. Moreover, all laboratories were able to identify similar differences between plasmas. In summary, we show that by using a standardized protocol for sample preparation, low technical variability can be achieved. Harmonization of all oxylipin extraction and analysis steps led to reliable, reproducible, and comparable oxylipin concentrations in independent laboratories, allowing the generation of biologically meaningful oxylipin patterns.

Published
2020

21. Studies in Zebra Fish and Rat Models Support Dual Blockade of EP2 and EP4 (Prostaglandin E2 Receptors Type 2 and 4) for Renoprotection in Glomerular Hyperfiltration and Albuminuria

Author

Kourpa, Aikaterini, Schulz, Angela, Mangelsen, Eva, Kaiser-Graf, Debora, Koppers, Nils, Stoll, Monika, Rothe, Michael, Bader, Michael, Purfürst, Bettina, Kunz, Severine, Gladytz, Thomas, Niendorf, Thoralf, Bachmann, Sebastian, Mutig, Kerim, Bolbrinker, Juliane, Panáková, Daniela, and Kreutz, Reinhold

Published
2023
Full Text
View/download PDF

23. Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Brouse, Gregory, Chan, John, Mehmi, Inderjit, Khalil, Maya, Duvivier, Herbert L., Gaba, Anu, Leuva, Harshraj, Thota, Ramya, Yost, Kathleen J., Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Subjects
*POLY(ADP-ribose) polymerase, *EPIDERMAL growth factor receptors, *CANCER patients, *METASTATIC breast cancer, *DRUG labeling
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with various solid tumors with germline or somatic BRCA1/2 mutations treated with talazoparib are reported. METHODS: Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Patients with germline BRCA -mutated human epidermal growth factor receptor 2–negative locally advanced or metastatic breast cancer were not eligible for this study. Primary end point was disease control (DC) determined by investigator assessment of objective response (OR) or stable disease (SD) of at least 16 weeks duration (SD16+). The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power = 0.82; α =.10). Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Twenty-eight patients (20 cancer types) with BRCA1/2 mutations were enrolled from December 2019 to September 2021 and collapsed into a single histology pooled cohort for analysis. All patients were evaluable for efficacy. One complete response, nine partial response, and six SD16+ were observed for DC and OR rates of 57% (one-sided 90% CI, 43 to 100) and 36% (95% CI, 19 to 56), respectively. The null hypothesis of a 15% DC rate was rejected (P <.001). Patients with OR had the following tumor types: breast (2), nonmelanoma skin, mesothelioma, stomach, uterus, non–small cell lung cancer, ovary, hepatocellular carcinoma, and pancreas. Thirteen patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to talazoparib. All were consistent with the drug label except bilirubin increase and hyponatremia (both grade 3 AEs). CONCLUSION: Talazoparib demonstrated antitumor activity in patients with advanced solid tumors and BRCA1/2 mutations, including cancer types for which poly ADP-ribose polymerase inhibitors are not yet US Food and Drug Administration–approved. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Olaparib in Patients With Pancreatic Cancer With BRCA1 / 2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Ahn, Eugene R., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Calfa, Carmen J., Alva, Ajjai S., Suhag, Vijay, Alese, Olatunji B., Dotan, Efrat, Hamid, Omid, Yang, Eddy S., Marr, Alissa S., Palmer, Martin C., Thompson, Forrest L., Yost, Kathleen J., Gregory, Abigail, Grantham, Gina N., Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Subjects
*CANCER patients, *PANCREATIC cancer, *ANTINEOPLASTIC agents, *OVERALL survival, *BRCA genes
Abstract

PURPOSE: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with advanced pancreatic cancer with BRCA1 / 2 mutations treated with olaparib are reported. METHODS: Eligible patients had advanced pancreatic cancer, measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options available. Genomic testing was performed in Clinical Laboratory Improvement Amendments–certified, College of American Pathologists-accredited site selected laboratories. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with BRCA1 / 2 mutations were enrolled from November 2016 to August 2019. The median number of reported previous therapies was 3 (range, 1-10). Two patients were not evaluable and excluded from efficacy analyses. Two patients with complete response, three with partial response and three with SD16+, were observed for DC and OR rates of 31% (90% CI, 18 to 40; P =.04) and 18% (95% CI, 6 to 37), respectively. The median PFS was 8 (95% CI, 8 to 15) weeks, and the median OS was 38 (95% CI, 21 to 65) weeks. Three patients had at least one drug-related grade 3 adverse event or serious adverse event of anemia, fever, or oral mucositis. CONCLUSION: Olaparib showed antitumor activity in patients with advanced pancreatic cancer with BRCA1 / 2 mutations extending findings of recent studies of olaparib in patients with this disease. @ASCO #TAPUR confirms and extends olaparib antitumor activity in pretreated patients w/BRCA1/2 mutated pancreatic cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Interaction of sortilin with apolipoprotein E3 enables neurons to use long-chain fatty acids as alternative metabolic fuel

Author

Willnow, Thomas, primary, Greda, Ania K, additional, Gomes, Jemila P, additional, Zurawska-Plaksej, Ewa, additional, Raphaela Fritsche-Guenther, Raphaela, additional, Rudolph, Ina-Maria, additional, Telugu, Narasimha S, additional, Coemert, Cagla, additional, Kirwan, Jennifer, additional, Kunz, Severine, additional, Rothe, Michael, additional, Diecke, Sebastian, additional, and Bross, Peter, additional

Published
2024
Full Text
View/download PDF

26. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Cannon, Timothy L., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Chiu, Vi K., additional, Hwang, Jimmy, additional, Vijayvergia, Namrata, additional, Alese, Olatunji B., additional, Dib, Elie G., additional, Duvivier, Herbert L., additional, Klute, Kelsey A., additional, Sahai, Vaibhav, additional, Ahn, Eugene R., additional, Bedano, Pablo, additional, Behl, Deepti, additional, Sinclair, Sarah, additional, Thota, Ramya, additional, Urba, Walter J., additional, Yang, Eddy S., additional, Grantham, Gina N., additional, Hinshaw, Dominique C., additional, Gregory, Abigail, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

27. Correction for Gupta et al., “Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration”

Author

Gupta, Saumya Shree, primary, Maetzig, Tobias, additional, Maertens, Goedele N., additional, Sharif, Azar, additional, Rothe, Michael, additional, Weidner-Glunde, Magdalena, additional, Galla, Melanie, additional, Schambach, Axel, additional, Cherepanov, Peter, additional, and Schulz, Thomas F., additional

Published
2024
Full Text
View/download PDF

29. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Meric-Bernstam, Funda, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Gutierrez, Rodolfo, Ahn, Eugene R., Cannon, Timothy L., Powell, Steven, Krauss, John C., Reynolds, Christopher M., von Mehren, Margaret, Behl, Deepti, Calfa, Carmen J., Duvivier, Herbert L., Kaplan, Henry G., Livingston, Michael B., Sharma, Manish R., Urba, Walter J., Grantham, Gina N., Hinshaw, Dominique C., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.

Published
2023
Full Text
View/download PDF

30. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Rohatgi, Nitin, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Pisick, Evan, Alese, Olatunji B., Reynolds, Christopher M., Thota, Ramya, Vaccaro, Gina M., von Mehren, Margaret, Arend, Rebecca C., Chiu, Vi K., Duvivier, Herbert L., Gold, Philip J., Hack, Keely, Marr, Alissa S., Winer, Arthur, Grantham, Gina N., Hinshaw, Dominique C., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.

Published
2023
Full Text
View/download PDF

31. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Ganti, Apar K., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Dib, Elie G., Duvivier, Herbert L., Ahn, Eugene R., Behl, Deepti, Borghaei, Hossein, Balmanoukian, Ani S., Gaba, Anu, Li, Rui, Osei-Boateng, Kwabena, Thota, Ramya, Grantham, Gina N., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.

Published
2023
Full Text
View/download PDF

32. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study

Author

Ahn, Eugene R., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ali-Ahmad, Hussein M., Chan, John, Maitland, Michael L., Patel, Sapna R., Reese, Zachary, Balmanoukian, Ani S., Drescher, Charles W., Li, Rui, Tsimberidou, Apostolia M., Leath, Charles A., III, OʼLone, Raegan, Grantham, Gina N., Halabi, Susan, and Schilsky, Richard L.

Published
2023
Full Text
View/download PDF

34. Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment

Author

Navarro, Susana, Quintana-Bustamante, Oscar, Sanchez-Dominguez, Rebeca, Lopez-Manzaneda, Sergio, Ojeda-Perez, Isabel, Garcia-Torralba, Aida, Alberquilla, Omaira, Law, Kenneth, Beard, Brian C., Bastone, Antonella, Rothe, Michael, Villanueva, Mariela, Ramirez, Juan C., Fañanas-Baquero, Sara, Nieto-Romero, Virginia, Molinos-Vicente, Andrea, Gutierrez, Sonia, Nicoletti, Eileen, García-Bravo, María, Bueren, Juan A., Schwartz, Jonathan D., and Segovia, Jose-Carlos

Published
2021
Full Text
View/download PDF

36. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency

Author

Punwani, Divya, Kawahara, Misako, Yu, Jason, Sanford, Ukina, Roy, Sushmita, Patel, Kiran, Carbonaro, Denise A, Karlen, Andrea D, Khan, Sara, Cornetta, Kenneth, Rothe, Michael, Schambach, Axel, Kohn, Donald B, Malech, Harry L, McIvor, R Scott, Puck, Jennifer M, and Cowan, Morton J

Subjects
severe combined immunodeficiency, Artemis, gene therapy, lentivirus, radiation sensitivity, Medical Biotechnology, Clinical Sciences, Biotechnology
Published
2017

41. Cell culture media notably influence properties of human mesenchymal stroma/stem-like cells from different tissues

Author

Winkel, Andreas, Jaimes, Yarúa, Melzer, Catharina, Dillschneider, Philipp, Hartwig, Henning, Stiesch, Meike, von der Ohe, Juliane, Strauss, Sarah, Vogt, Peter M., Hamm, Anika, Burmeister, Laura, Roger, Yvonne, Elger, Kirsten, Floerkemeier, Thilo, Weissinger, Eva M., Pogozhykh, Olena, Müller, Thomas, Selich, Anton, Rothe, Michael, Petri, Susanne, Köhl, Ulrike, Hass, Ralf, and Hoffmann, Andrea

Published
2020
Full Text
View/download PDF

42. Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID

Author

Garcia-Perez, Laura, van Eggermond, Marja, van Roon, Lieke, Vloemans, Sandra A., Cordes, Martijn, Schambach, Axel, Rothe, Michael, Berghuis, Dagmar, Lagresle-Peyrou, Chantal, Cavazzana, Marina, Zhang, Fang, Thrasher, Adrian J., Salvatori, Daniela, Meij, Pauline, Villa, Anna, Van Dongen, Jacques J.M., Zwaginga, Jaap-Jan, van der Burg, Mirjam, Gaspar, H. Bobby, Lankester, Arjan, Staal, Frank J.T., and Pike-Overzet, Karin

Published
2020
Full Text
View/download PDF

43. Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy

Author

Brendel, Christian, Negre, Olivier, Rothe, Michael, Guda, Swaroopa, Parsons, Geoff, Harris, Chad, McGuinness, Meaghan, Abriss, Daniela, Tsytsykova, Alla, Klatt, Denise, Bentler, Martin, Pellin, Danilo, Christiansen, Lauryn, Schambach, Axel, Manis, John, Trebeden-Negre, Helene, Bonner, Melissa, Esrick, Erica, Veres, Gabor, Armant, Myriam, and Williams, David A.

Published
2020
Full Text
View/download PDF

44. Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1

Author

Beschorner, Niklas, primary, Künzle, Paul, additional, Voges, Maike, additional, Hauber, Ilona, additional, Indenbirken, Daniela, additional, Nakel, Jacqueline, additional, Virdi, Sanamjeet, additional, Bradtke, Peter, additional, Lory, Niels Christian, additional, Rothe, Michael, additional, Paszkowski-Rogacz, Maciej, additional, Buchholz, Frank, additional, Grundhoff, Adam, additional, Schambach, Axel, additional, Thirion, Christian, additional, Mittrücker, Hans-Willi, additional, Schulze zur Wiesch, Julian, additional, Hauber, Joachim, additional, and Chemnitz, Jan, additional

Published
2024
Full Text
View/download PDF

45. KCNQ5 Controls Perivascular Adipose Tissue–Mediated Vasodilation

Author

Tsvetkov, Dmitry, primary, Schleifenbaum, Johanna, additional, Wang, Yibin, additional, Kassmann, Mario, additional, Polovitskaya, Maya M., additional, Ali, Mohamed, additional, Schütze, Sebastian, additional, Rothe, Michael, additional, Luft, Friedrich C., additional, Jentsch, Thomas J., additional, and Gollasch, Maik, additional

Published
2024
Full Text
View/download PDF

47. Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Al Baghdadi, Tareq, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Yost, Kathleen J, additional, Chiu, Vi Kien, additional, Duvivier, Herbert Leon, additional, McKean, Meredith, additional, Rueter, Jens, additional, Taylor, Mark A., additional, Grantham, Gina N., additional, Gregory, Abby, additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

48. Acyl-CoA Dehydrogenase Drives Heat Adaptation by Sequestering Fatty Acids

Author

K., Dengke, Li, Zhijie, Lu, Alice Y, Sun, Fang, Chen, Sidi, Rothe, Michael, Menzel, Ralph, Sun, Fei, and Horvitz, H Robert

Subjects
Nutrition, Heart Disease, Prevention, Cardiovascular, Acyl-CoA Dehydrogenase, Adaptation, Physiological, Amino Acid Sequence, Animals, Caenorhabditis elegans, Caenorhabditis elegans Proteins, Fatty Acids, Hot Temperature, Models, Molecular, Molecular Sequence Data, Sequence Alignment, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Cells adapt to temperature shifts by adjusting levels of lipid desaturation and membrane fluidity. This fundamental process occurs in nearly all forms of life, but its mechanism in eukaryotes is unknown. We discovered that the evolutionarily conserved Caenorhabditis elegans gene acdh-11 (acyl-CoA dehydrogenase [ACDH]) facilitates heat adaptation by regulating the lipid desaturase FAT-7. Human ACDH deficiency causes the most common inherited disorders of fatty acid oxidation, with syndromes that are exacerbated by hyperthermia. Heat upregulates acdh-11 expression to decrease fat-7 expression. We solved the high-resolution crystal structure of ACDH-11 and established the molecular basis of its selective and high-affinity binding to C11/C12-chain fatty acids. ACDH-11 sequesters C11/C12-chain fatty acids and prevents these fatty acids from activating nuclear hormone receptors and driving fat-7 expression. Thus, the ACDH-11 pathway drives heat adaptation by linking temperature shifts to regulation of lipid desaturase levels and membrane fluidity via an unprecedented mode of fatty acid signaling.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results